Acute and Impaired Wound Healing

Demidova-Rice, Tatiana N.; Hamblin, Michael R.; Herman, Ira M.

doi:10.1097/01.asw.0000418541.31366.a3

Cited by 171 publications

(112 citation statements)

References 180 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…47,48 Zebrafish epithelial–like cells migrate along the body of the fish to reach the tip of the tail in response to a gradient of SDF-1; interestingly, in the absence of SDF-1 or its receptor (CXCR4) cells fail to achieve directional migration. 49 Intravascular chemokine gradients and also formyl peptide signals generated from necrotic cells guide neutrophils toward the injury. 50 In summary, wound healing initiated upon injury is a highly coordinated process that is controlled by a number of cell types and mediators in the epithelial milieu.…”

Section: Epithelial Wound Healingmentioning

confidence: 99%

Wound repair: role of immune–epithelial interactions

Leoni¹,

Neumann²,

et al. 2015

View full text Add to dashboard Cite

The epithelium serves as a highly selective barrier at mucosal surfaces. Upon injury, epithelial wound closure is orchestrated by a series of events that emanate from the epithelium itself as well as by the temporal recruitment of immune cells into the wound bed. Epithelial cells adjoining the wound flatten out, migrate, and proliferate to rapidly cover denuded surfaces and re-establish mucosal homeostasis. This process is highly regulated by proteins and lipids, proresolving mediators such as Annexin A1 protein and resolvins released into the epithelial milieu by the epithelium itself and infiltrating innate immune cells including neutrophils and macrophages. Failure to achieve these finely tuned processes is observed in chronic inflammatory diseases that are associated with non-healing wounds. An improved understanding of mechanisms that mediate repair is important in the development of therapeutics aimed to promote mucosal wound repair.

show abstract

Section: Epithelial Wound Healingmentioning

confidence: 99%

Wound repair: role of immune–epithelial interactions

Leoni¹,

Neumann²,

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Therefore, wound treatment using exogenous PDGF has been studied and was found to be beneficial for patients with chronic wounds [74,75]. As a result of FDA approval, PDGF-BB has been extensively used for treating diabetic ulcers [75,76]. Despite this approval, there have been reports showing a limited clinical success.…”

Section: Regenerative Therapies For Skin Wound Managementmentioning

confidence: 99%

“…In this regard, different types of systems have been reported such as proteinaceous ECM-derived, carbohydrate-based and synthetic vehicles. Several biodegradable or biocompatible delivery systems have been considered as safe by the FDA [76]. Still, a number of other challenges deserve more attention, including: i) increasing stability of encapsulated growth factors in the biomaterial/construct to allow release for longer periods, ii) difficulties in upscaling and iii) defining a suitable compartmentalization to allow multiple factor release with specific kinetics.…”

Section: Hurdles In Regenerative Therapies For Skin Wound Healing Andmentioning

confidence: 99%

“…Moreover, a single factor may not be sufficient as a therapeutic tool because of the complexity and perseverance of a chronic wound. Therefore, sustained GF delivery systems with a combined and/or case specific approach might be necessary to enable optimal wound healing and closure [76,78,79]. Recently, a combination of AMD3100 (which mobilizes marrow-derived progenitor cell) and PDGF-BB therapy has synergistically shown to improve progenitor mobilization and trafficking, resulting in significantly improved diabetic wound closure and neovascularization [80].…”

Section: Regenerative Therapies For Skin Wound Managementmentioning

confidence: 99%

“…In fact, these lipids function synergistically with growth factors, stimulating their function and enhancing wound healing. For this reason, the combination of growth factors with other bio-active lipids might generate some interesting findings [76]. Moreover in some cases there is insufficient bioavailability of growth factors, because of reduced synthesis and/or enhanced degradation in chronic wounds [119].…”

Section: Hurdles In Regenerative Therapies For Skin Wound Healing Andmentioning

confidence: 99%

See 2 more Smart Citations

Regenerative Skin Wound Healing in Mammals: State-of-the-Art on Growth Factor and Stem Cell Based Treatments

Borena

Martens

Broeckx

et al. 2015

Cell Physiol Biochem

168

112

View full text Add to dashboard Cite

Mammal skin has a crucial function in several life-preserving processes such as hydration, protection against chemicals and pathogens, initialization of vitamin D synthesis, excretion and heat regulation. Severe damage of the skin may therefore be life-threatening. Skin wound repair is a multiphased, yet well-orchestrated process including the interaction of various cell types, growth factors and cytokines aiming at closure of the skin and preferably resulting in tissue repair. Regardless various therapeutic modalities targeting at enhancing wound healing, the development of novel approaches for this pathology remains a clinical challenge. The time-consuming conservative wound management is mainly restricted to wound repair rather than restitution of the tissue integrity (the so-called “restitutio ad integrum”). Therefore, there is a continued search towards more efficacious wound therapies to reduce health care burden, provide patients with long-term relief and ultimately scarless wound healing. Recent in vivo and in vitro studies on the use of skin wound regenerative therapies provide encouraging results, but more protracted studies will have to determine whether the effect of observed effects are clinically significant and whether regeneration rather than repair can be achieved. For all the aforementioned reasons, this article reviews the emerging field of regenerative skin wound healing in mammals with particular emphasis on growth factor- and stem cell-based therapies.

show abstract